Royal Bank Of Canada Forecasts Strong Price Appreciation for GRAIL (NASDAQ:GRAL) Stock

GRAIL (NASDAQ:GRAL) had its target price boosted by equities researchers at Royal Bank Of Canada from $84.00 to $100.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price objective suggests a potential downside of 17.65% from the company’s current price.

Several other equities research analysts have also issued reports on the stock. Robert W. Baird raised their target price on shares of GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a report on Tuesday, September 22nd. TD Cowen raised their price objective on shares of GRAIL from $88.00 to $180.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research report on Thursday, October 15th. Guggenheim upped their target price on GRAIL from $75.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, Morgan Stanley increased their price target on GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a report on Monday, October 12th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, GRAIL currently has an average rating of “Hold” and a consensus target price of $121.40.

GRAIL Price Performance

Shares of GRAIL stock traded up $2.31 on Thursday, reaching $121.44. The company had a trading volume of 756,007 shares, compared to its average volume of 962,697. The firm has a market cap of $5.42 billion, a price-to-earnings ratio of -12.78 and a beta of 2.86. The firm’s 50-day moving average price is $117.15 and its two-hundred day moving average price is $79.33. GRAIL has a 1 year low of $41.50 and a 1 year high of $166.48.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($2.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.45) by $0.24. The company had revenue of $37.53 million during the quarter, compared to the consensus estimate of $44.21 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. As a group, analysts anticipate that GRAIL will post -10.07 EPS for the current year.

Insider Transactions at GRAIL

In related news, insider Andrew Partridge sold 7,873 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $1,152,528.47. Following the transaction, the insider owned 155,865 shares of the company’s stock, valued at $22,817,077.35. This trade represents a 4.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Aaron Freidin sold 23,619 shares of GRAIL stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $146.39, for a total transaction of $3,457,585.41. Following the sale, the chief financial officer owned 225,364 shares of the company’s stock, valued at $32,991,035.96. The trade was a 9.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 129,944 shares of company stock worth $14,832,805. Insiders own 1.83% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Fifth Third Bancorp raised its position in GRAIL by 15,733.3% during the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after purchasing an additional 472 shares in the last quarter. Geneos Wealth Management Inc. increased its position in GRAIL by 160.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after purchasing an additional 360 shares during the period. Allworth Financial LP purchased a new position in GRAIL during the 2nd quarter valued at about $35,000. North Star Investment Management Corp. raised its holdings in shares of GRAIL by 809.1% in the 3rd quarter. North Star Investment Management Corp. now owns 300 shares of the company’s stock valued at $42,000 after purchasing an additional 267 shares in the last quarter. Finally, Root Financial Partners LLC bought a new stake in shares of GRAIL in the 3rd quarter valued at about $44,000.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Royal Bank of Canada raised its price target to $100 from $84, signaling a more favorable valuation view than before, although it kept a “sector perform” rating. RBC target update
• Neutral Sentiment: Goldman Sachs assigned GRAIL a “Hold,” and RBC also maintained its “Hold” view, reflecting a wait-and-see stance rather than a strong near-term catalyst. Goldman Sachs rating RBC rating
• Negative Sentiment: RBC’s new $100 target remains below the stock’s recently quoted $121.44 price, implying the analyst sees limited upside at that level despite the increase in its estimate. RBC target update
• Negative Sentiment: GRAIL is cutting Galleri prices to support adoption ahead of an expected early-2027 FDA decision, but lower pricing could weigh on revenue growth and margins. Its latest quarter also showed revenue of $37.54 million below the $44.21 million consensus estimate, despite a smaller-than-expected per-share loss. Q3 pricing and FDA outlook Q3 financial results

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.